Apolipoprotein A-I deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:425OMIM:618463E78.6
Who is this for?
Show terms as
6Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Apolipoprotein A-I (apo A-I) deficiency is a rare inherited disorder of lipoprotein metabolism caused by mutations in the APOA1 gene, which encodes the major protein component of high-density lipoprotein (HDL) cholesterol. This condition is also known as familial hypoalphalipoproteinemia or analphalipoproteinemia when HDL is completely absent. Apo A-I plays a critical role in reverse cholesterol transport — the process by which excess cholesterol is removed from tissues and transported to the liver for excretion. When apo A-I is deficient or absent, HDL cholesterol levels are markedly reduced or undetectable, leading to impaired cholesterol clearance from the body. The disease primarily affects the cardiovascular system, the eyes, and the skin. Patients are at significantly increased risk for premature coronary artery disease and atherosclerosis, often presenting with symptomatic cardiovascular events in early adulthood. Corneal opacification (corneal clouding) is a hallmark feature and may develop in childhood or early adulthood, potentially impairing vision. Some patients also develop xanthomas — yellowish deposits of cholesterol in the skin and tendons — due to abnormal lipid accumulation. In certain variants, amyloidosis affecting the kidneys, liver, or other organs has been reported, caused by deposition of amyloid fibrils derived from mutant apo A-I protein. There is currently no specific curative therapy for apo A-I deficiency. Management focuses on aggressive cardiovascular risk reduction, including lifestyle modifications (diet, exercise, smoking cessation) and lipid-lowering medications such as statins. Corneal transplantation may be considered for significant visual impairment due to corneal opacities. Regular cardiovascular monitoring and screening for complications such as amyloidosis are recommended. Research into HDL-targeted therapies and apo A-I replacement strategies is ongoing but remains largely investigational.

Also known as:

Clinical phenotype terms— hover any for plain English:

AtherosclerosisHP:0002621Abnormal circulating lipid concentrationHP:0003119Decreased HDL cholesterol concentrationHP:0003233Opacification of the corneal stromaHP:0007759XanthomatosisHP:0000991XanthelasmaHP:0001114Premature coronary artery atherosclerosisHP:0005181
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Apolipoprotein A-I deficiency.

View clinical trials →

No actively recruiting trials found for Apolipoprotein A-I deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Apolipoprotein A-I deficiency community →

Specialists

6 foundView all specialists →
RM
Robert D Fishberg, MD
SPRINGFIELD, NJ
Specialist
PI on 1 active trial
GM
Greg Bondy, MD
Specialist
PI on 1 active trial1 Apolipoprotein A-I deficiency publication
DP
David Reboussin, PhD
Specialist
PI on 1 active trial
ES
Erik SG Stroes
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Apolipoprotein A-I deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Apolipoprotein A-I deficiencyForum →

No community posts yet. Be the first to share your experience with Apolipoprotein A-I deficiency.

Start the conversation →

Latest news about Apolipoprotein A-I deficiency

Disease timeline:

New recruiting trial: LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study

A new clinical trial is recruiting patients for Apolipoprotein A-I deficiency

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Apolipoprotein A-I deficiency

What is Apolipoprotein A-I deficiency?

Apolipoprotein A-I (apo A-I) deficiency is a rare inherited disorder of lipoprotein metabolism caused by mutations in the APOA1 gene, which encodes the major protein component of high-density lipoprotein (HDL) cholesterol. This condition is also known as familial hypoalphalipoproteinemia or analphalipoproteinemia when HDL is completely absent. Apo A-I plays a critical role in reverse cholesterol transport — the process by which excess cholesterol is removed from tissues and transported to the liver for excretion. When apo A-I is deficient or absent, HDL cholesterol levels are markedly reduced

Which specialists treat Apolipoprotein A-I deficiency?

6 specialists and care centers treating Apolipoprotein A-I deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.